ᓄᕙᒡᔪᐊᕐᓇᖅ-19 mRNA ᑲᐳᑏᑦ
Pfizer-BioNTech ᑲᐳᑎ ᐊᒻᒪᓗ ᒪᑑᓇ ᑲᐳᑎ
ᐋᓐᓂᐊᖃᖅᑕᐃᓕᒪᔪᓕᕆᔨᒃᑯᑦ - ᓱᓕᓂᕐᓂᒃ ᑎᑎᕋᖅᓯᒪᔪᑦ

ᑲᐱᔭᐅᔾᔪᑏᑦ ᐃᓚᒋᔭᐅᔪᑦ ᐱᒻᒪᕆᐅᓂᖅᐹᓂᒃ ᐱᐊᓂᒃᑕᐅᓯᒪᔪᓂᑦ ᐋᓐᓂᐊᖃᖅᑕᐃᓕᒪᔪᓕᕆᔨᓄᑦ. 50 ᐅᑭᐅᓂᑦ ᐊᓂᒍᖅᑐᓂᑦ, ᑲᐱᔭᐅᔾᔪᑏᑦ ᓄᖑᑎᕆᓯᒪᔪᑦ, ᓄᖅᑲᖓᑎᑦᑎᕐᓗᑎᒃ ᐊᒻᒪᓗ ᐊᐅᓚᑦᑎᓂᕐᒧᑦ ᐋᓐᓂᐊᕐᓂᒃ ᑕᐃᒪᐅᒐᔪᑦᑎᐊᓚᐅᖅᑐᓂᒃ ᑲᓇᑕᒥᑦ.[1] ᑲᐱᔭᐅᔾᔪᑏᑦ ᐃᑲᔪᖃᑦᑕᖅᑐᑦ ᑎᒥᑉᑎᖕᓃᑦᑐᓂᒃ ᐋᓐᓂᐊᕐᒧᑦ ᐋᖅᑭᐅᒪᔪᒥᑦ ᐃᓕᑕᖅᓯᓂᕐᒧᑦ ᐊᒻᒪᓗ ᐱᐅᖏᑦᑐᓂᒃ ᐋᓐᓂᐊᓕᕈᑕᐅᔪᖕᓇᖅᑐᓂᒃ ᐱᑕᕐᑲᖅᑕᐃᓕᑎᑦᑎᓂᕐᒧᑦ ᐊᒻᒪᓗ ᐋᓐᓂᐊᕈᑎᓂᒃ ᐋᓐᓂᐊᖅᑖᖅᑎᑦᑎᖃᑦᑕᖅᑐᓂᒃ.

ᓱᓇᐅᕙ ᓄᕙᒡᔪᐊᕐᓇᖅ-19 mRNA ᑲᐳᑏᑦ?

ᓄᕙᒡᔪᐊᕐᓇᖅ-19 mRNA ᑲᐳᑏᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᑖᖅᑕᐃᓕᓂᕐᒧᑦ. mRNA ᑲᐳᑏᑦ ᐃᓕᓐᓂᐊᖅᑎᑦᑎᖃᑦᑕᖅᑐᑦ ᑎᒥᑉᑎᖕᓃᑦᑐᓂᒃ ᓱᓇᓕᐅᕆᓂᕐᒥᒃ ᐱᒋᐊᖅᑎᑦᑎᓂᐊᖅᑐᒥᒃ ᑎᒥᑉᑎᖕᓂᑦ ᐋᓐᓂᐊᖅᑖᖅᑕᐃᓕᓂᕐᒧᑦ ᐅᑉᐊᓂᕐᒥᒃ ᐊᑐᙱᓪᓗᑎᒃ ᐆᒪᓂᖃᖅᑐᓂᒃ ᐋᓐᓂᐊᕐᓂᕐᒥᒃ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᑖᖅᑎᑦᑎᔪᒥᒃ. ᐱᒋᐊᖅᑎᑕᐅᒃᐸᑦ, ᑎᒥᕗᑦ ᐱᑖᖅᑎᑦᑎᑕᐃᓕᓂᕐᒧᑦ ᐊᑐᖅᑐᓂᒃ ᐱᓕᐅᕆᖃᑦᑕᖅᑐᑦ. ᐱᑖᖅᑎᑦᑎᑕᐃᓕᓂᕐᒧᑦ ᐊᑐᖅᑐᑦ ᐅᕙᑉᑎᖕᓂᑦ ᒥᐊᓂᖅᓯᔪᑦ ᐋᓐᓂᐊᖅᑖᕐᓂᕐᒧᑦ ᐋᓐᓂᐊᕈᑎᓪᓚᑦᑖᖅ ᑎᒥᑉᑎᖕᓄᐊᖅᐸᑦ ᓯᕗᓂᒃᓴᒥᑦ.

"RNA" ᑐᑭᖅᑲᖅᑐᖅ ribonucleic acid-ᒧᑦ, ᒥᑭᔪᖅ ᑎᒥᑉᑎᖕᓃᑦᑐᖅ ᖃᓄᐃᓕᐅᕐᑯᐅᔪᖅ ᒥᐊᓂᖅᓯᔾᔪᑎᓄᑦ. **ᐅᖃᐅᔾᔨᓂᖅ RNA (mRNA)** ᑲᐳᑏᑦ ᐃᓗᓕᖃᖅᑐᑦ ᖃᓄᐃᓕᐅᕐᑯᐅᔪᖅ SARS-CoV-2-ᓕᐅᖅᓱᑎᒃ. ᑖᒻᓇ ᖄᖓᓃᑦᑐᖅ ᐋᓐᓂᐊᕐᓇᐅᑉ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᑖᖅᑎᑦᑎᑉᐳᓂ.

mRNA ᑲᐳᑏᑦ ᐊᓯᐊᙳᖅᓯᔪᖕᓇᙱᑦᑐᖅ ᐃᓅᑉ ᑭᓇᐅᔾᔪᑎᖏᓐᓂᑦ.

ᐃᓄᒃ ᑲᐱᔭᐅᖃᑦᑕᖅᑐᖅ, ᑎᒥᖓᓃᑦᑐᑦ ᐅᖃᓕᒫᕐᓂᐊᕐᒪᑕ ᖃᓄᐃᓕᐅᕐᑯᐅᓂᕐᒧᑦ ᓲᕐᓗ ᐃᓚᒋᔭᐅᔪᓂᒃ ᐊᒻᒪᓗ ᐋᓐᓂᐊᖅᑖᖅᑕᐃᓕᔾᔪᑎᓕᐅᖅᓱᓂ. ᑭᖑᓂᐊᒍᑦ ᐋᓐᓂᐊᖅᑖᖅᑕᐃᓕᔾᔪᑎᓕᐅᖅᑲᖅᑎᓪᓗᒍ, ᑎᒥᑉᑎᖕᓃᑦᑐᖅ ᓯᕐᑯᐊᑎᖅᓱᒍ ᖃᓄᐃᓕᐅᕐᑯᐅᔪᑦ ᐊᒻᒪᓗ ᐱᑕᖃᕈᖕᓃᖅᓱᒋᑦ.

ᑎᒥᑉᑎᖕᓃᑦᑐᖅ ᑕᑯᒃᓴᐅᑎᕐᓱᓄᐅᒃ ᐋᓐᓂᐊᖅᑖᖅᑕᐃᓕᔾᔪᑎᓂ ᖄᖓᓂᑦ ᑖᑉᓗᒪ. ᑎᒥᑉᑎᖕᓄᑦ ᐋᓐᓂᐊᕐᓂᕐᒧᑦ ᐊᔪᙱᔾᔪᑏᑦ ᐃᓕᑕᖅᓯᔪᑦ ᐋᓐᓂᐊᖅᑖᖅᑕᐃᓕᔾᔪᑎ ᑕᐃᑲᓃᑦᑕᒐᐊᖅᙱᒻᒪᑦ ᐊᒻᒪᓗ ᐱᕈᐃᑎᑦᑎᓕᖅᓱᓂ ᑎᒥᑉᑎᖕᓄᑦ ᐋᓐᓂᐊᕐᓂᕐᒧᑦ ᐅᑉᐊᔾᔪᑎᓂᒃ ᐋᓐᓂᐊᖅᑖᖅᑕᐃᓕᔾᔪᑎᓕᐅᖅᓱᓂ. **ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᑖᔅᔭᙱᑦᑐᑎᑦ ᑲᐱᔭᐅᓗᑎᑦ.**

ᓱᓇᑐᐃᓐᓇᓕᕆᔩᑦ ᐊᒻᒪᓗ ᐃᓗᐊᖅᓴᐅᑎᑦᓕᐅᖅᑏᑦ ᑲᐳᑎᓕᐅᖅᓯᒪᔪᑦ ᐱᒻᒪᕆᐅᓂᖅᓴᓄᑦ ᐱᔭᐅᔭᕆᐊᖅᑲᕐᓂᖅᓴ ᐅᓇᑕᕐᓂᐊᕐᓗᒍ ᓄᓇᔪᐊᕐᒧᑦ ᓯᐊᒻᒪᒃᐸᕐᓕᐊᖅᓴ ᓄᕙᒡᔪᐊᕐᓇᖅ-19. Pfizer-BioNTech-ᑯᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19 ᐋᓐᓂᐊᓗᐊᖅᑕᐃᓕᔾᔪᑎᒧᑦ ᑲᐳᑎᖓᑦ (Tozinameran ᐅᕝᕙᓘᓐᓃᑦ BNT162b2) ᐊᒻᒪᓗ ᒪᑑᓇ ᓄᕙᒡᔪᐊᕐᓇᖅ-19 ᐋᓐᓂᐊᓗᐊᖅᑕᐃᓕᔾᔪᑎᒧᑦ ᑲᐳᑎᓕᕆᔩᑦ (mRNA-1273) ᓯᕗᓪᓕᖅᐸᐅᔪᒃ ᒪᕐᕉᒃ ᓄᕙᒡᔪᐊᕐᓇᖅ-19 ᐋᓐᓂᐊᓗᐊᖅᑕᐃᓕᔾᔪᑎᒧᑦ ᑲᐳᑏᑦ ᓈᒻᒪᒋᔭᐅᔪᑦ ᑲᓇᑕᒥᑦ ᐋᓐᓂᐊᖅᑖᖅᑕᐃᓕᒪᔪᓕᕆᔨᒃᑯᓐᓄᑦ.

ᑲᓇᑕᒥᑦ ᐋᓐᓂᐊᖅᑖᖅᑕᐃᓕᒪᔪᓕᕆᔨᒃᑯᑦ ᑐᓂᓯᓚᐅᖅᑐᑦ ᑕᒪᐃᓐᓄᑦ Pfizer-BioNTech-ᑯᓐᓄᑦ ᐊᒻᒪᓗ ᒪᑑᓇ ᐋᓐᓂᐊᓗᐊᖅᑕᐃᓕᔾᔪᑎᒧᑦ ᑲᐳᑎᓕᕆᔩᓄᑦ ᐱᔭᐅᓂᖏᓐᓄᑦ ᐱᔪᓐᓇᖅᑎᑦᑎᐸᓗᑎᒃ ᖃᓄᐃᖓᔭᕆᐊᖅᑖᖅᑐᖅᑐᖅᑎᒃ ᐃᑲᔪᕐᓂᐊᕐᓗᑐᒃ ᐱᔭᐅᔫᓕᓂᐊᕐᓗᑐᒃ ᓄᕙᒡᔪᐊᕐᓇᖅ-19 ᐋᓐᓂᐊᓗᐊᖅᑕᐃᓕᔾᔪᑎᒧᑦ ᑲᐳᑎᑦ. ᑲᓇᑕᒥᑦ ᐋᓐᓂᐊᖅᑖᖅᑕᐃᓕᒪᔪᓕᕆᔨᒃᑯᑦ ᑕᐃᒪᓐᓄᑦ ᐱᓂᐊᕐᓂᕋᓚᐅᖅᑐᒃ ᐋᓐᓂᐊᖅᑖᖅᑕᐃᓕᒪᓂᕐᒧᑦ ᐱᕐᑯᑎᓂᒃ ᐃᑲᔫᑎᑦ ᐊᖏᓂᖅᓴᐅᑉᐸᑕ ᐅᓗᓇᐊᓇᕐᓂᐅᔪᖕᓇᖅᑐᓂᒃ. ᓈᒻᒪᒋᔭᐅᓂᖓ ᐋᓐᓂᐊᓗᐊᖅᑕᐃᓕᓂᕐᒧᑦ ᑲᐳᑎ ᐃᑲᔪᖅᑐᖅᑕᐅᔪᖅ ᖃᐅᔨᒪᓐᓇᐅᑎᖃᕐᓂᖓᓄᑦ ᐅᓗᓇᐊᓇᙱᓐᓂᖓᓂᒃ, ᐊᑑᑎᖃᕐᓂᖓᓄᑦ ᐊᒻᒪᓗ ᐱᑦᑕᐅᔪᑉᓗᓂ ᖃᓄᐃᖓᓂᒃ. ᓱᕗᓪᓕᖅᐸᒥᒃ ᖃᓄᐃᖓᓂᐅᔪᑦ ᐃᓗᐊᖅᓴᐃᓂᕐᒧᑦ ᐆᒃᑐᕋᐅᑎᓂᑦ ᐅᖃᖅᑐᑦ Pfizer-BioNTech-ᑯᑦ ᐊᒻᒪᓗ ᒪᑑᓇ ᐋᓐᓂᐊᓗᐊᖅᑕᐃᓕᓂᕐᒧᑦ ᑲᐳᑎᓕᕆᔩᑯᑦ ᖃᐅᔨᑎᑦᑎᓯᒪᔪᑦ 95%-ᓂᑦ ᐊᒻᒪᓗ 94%-ᓂᑦ ᐊᑑᑎᖃᕐᓂᖓᓄᑦ, ᓇᐃᑦᑑᔪᒥᑦ ᐃᓄᐃᑦ ᖃᐅᔨᓴᐃᕝᕕᖕᒥᑦ ᓇᓗᓇᐃᖅᑕᐅᔪᓂᒃ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᑖᖅᑕᐃᓕᒪᑎᓪᓗᒋᑦ.

ᑖᑉᑯᐊᒃ ᒪᕐᕉᒃ ᓄᕙᒡᔪᐊᕐᓇᖅ-19 mRNA ᑲᐳᑏᑦ ᑐᓂᔭᐅᓂᐊᖅᑐᑦ ᒫᓂᑑᑉᒥᑦ ᑲᐱᔭᐅᓗᑎᒃ ᓂᕿᐊᒍᑦ ᑕᓕᐊᒍᑦ. ᓇᓗᓇᐃᔭᖅᓯᒪᔪᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19 ᐋᓐᓂᐊᓗᐊᖅᑕᐃᓕᔾᔪᑎᒧᑦ ᑲᐳᑎᓄᑦ ᐊᓯᐊᙳᕈᖕᓇᖅᑐᑦ ᖃᐅᔨᔾᔪᑕᐅᔪᑦ ᐊᓯᐊᙳᖅᑉᑉᓕᐊᖅᑉᑕ. ᐅᖃᖃᑎᒋᓗᒋᑦ ᐋᓐᓂᐊᖅᑖᖅᑕᐃᓕᒪᔪᓕᕆᔨᑎᑦ ᓱᓇᑐᐃᓐᓇᓂᒃ ᐊᐱᖅᑯᑎᖃᕈᕕᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19 mRNA ᑲᐳᑏᑦ ᒥᒃᓵᓄᑦ.

ᓄᕙᒡᔪᐊᕐᓇᖅ-19 ᐋᓐᓂᐊᓗᐊᖅᑕᐃᓕᔾᔪᑎᒧᑦ ᑲᐳᑏᑦ ᒥᐊᓂᖅᓯᓂᖅᙱᑦᑐᑦ ᐋᓐᓂᐊᕐᓂᕐᒧᑦ ᑲᐱᔭᐅᖃᑦᑕᕈᑕᐅᔪᑦᑐᖅᓄᑦ ᐊᓯᖏᓐᓄᑦᓗᓐᓃᑦ ᐋᓐᓂᐊᕐᓇᐅᔪᑦ ᐊᒻᒪᓗ ᐹᒃᑎᐅᕆᔭᓄᑦ ᐋᓐᓂᐊᓕᕈᑎᓄᑦ.

ᑭᑐᑦ ᑲᐱᔭᐅᔭᕆᐊᖅᑲᖅᐸᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19 ᐋᓐᓂᐊᓗᐊᖅᑕᐃᓕᔾᔪᑎᒧᑦ ᑲᐳᑎᒧᑦ?

ᓄᕙᒡᔪᐊᕐᓇᖅ-19 ᐋᓐᓂᐊᓗᐊᖅᑕᐃᓕᔾᔪᑎᒧᑦ ᑲᐳᑏᑦ ᒪᓂᒪᓕᕋᑦᑕᓂᐊᖅᑐᖅ ᒫᓂᑑᐸᒥᐅᓗᒃᑖᓄᑦ. ᑲᐳᑏᑦ ᐊᒥᒐᕐᒪᑕ, ᒫᓂᑑᐸ ᖃᐅᔨᓚᐅᖅᑐᑦ ᑭᑐᓂᒃ ᓯᕗᓪᓕᖅᐸᐅᑎᔭᐅᔭᕆᐊᖅᑲᖅᑐᓂᒃ ᓯᕗᓪᓕᖅᐹᒥᑦ ᑲᐳᑎᓄᑦ ᒪᓕᒃᓗᑎᑦ ᐃᒪᓐᓈᖅᑑᑎᖏᑦ ᑲᐱᔭᐅᔾᔪᑏᑦ ᑲᓇᑕᒥᑦ ᐅᖃᐅᔨᔾᔪᑎᒧᑦ ᐋᓐᓂᐊᖅᑕᐃᓕᒪᓂᕐᒧᑦ ᑲᐳᑎᓄᑦ ᑲᑎᒪᔨᕋᓛᓄᑦ (NACI) ᐊᒻᒪᓗ ᐱᓕᕆᖃᑎᖃᖅᓗᑎᒃ ᐃᓄᓗᒃᑖᑦ ᐋᓐᓂᐊᖃᖅᑕᐃᓕᒪᓂᖏᓐᓄᑦ ᖃᐅᔨᒪᓂᖃᖅᑐᓂᒃ ᑲᓇᑕᒃᑖᕐᒥᑦ ᑲᓇᑕᓗᒃᑖᕐᒧᑦ ᐋᔾᐅᔭᖏᑦᑐᑦ ᐅᖃᐅᔨᔾᔪᑎᒧᑦ ᑲᑎᒪᔨᐊᓛᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ. ᓱᕗᓪᓕᖅᐸᐅᑎᔭᐅᔭᕆᐊᓕᖕᓄᑦ ᐃᓚᐅᔪᑦ:

- ᐋᓐᓂᐊᖃᖅᑕᐃᓕᒪᔪᓕᕆᔩᑦ ᐊᑲᑐᐊᓂᖃᖅᑐᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᐅᐸᓗᐊᓂᕐᒧᑦ,
- ᐃᓄᐃᑦ ᑲᑎᕝᕕᖃᖅᑐᒥᒃ ᐊᖏᕋᖃᖅᑐᑦ ᓲᕐᓗ ᐊᑯᓂᐅᔪᒥᒃ ᑲᒪᒋᔭᐅᕝᕕᑦ, ᐃᑲᔪᖅᑕᐅᔭᕆᐊᖃᖅᑐᓄᑦ ᐊᖏᕋᕆᔭᐅᔪᑦ, ᐱᓕᕆᐊᒥᖕᓂᒃ ᓄᖅᑲᐅᒪᓕᖅᑐᓄᑦ ᐊᖏᕋᕆᔭᐅᔪᑦ, ᐊᒻᒪᓗ ᐋᓐᓂᐊᖃᐃᓐᓇᖅᑐᓂᒃ ᑲᒪᖃᑦᑕᖅᑐᑦ ᐋᓐᓂᐊᕐᕕᑦ,
- ᐃᓐᓇᐅᓂᖅᓴᐅᔪᑦ ᐃᓐᓇᐃᑦ ᐱᒋᐊᕐᓗᑎᒃ 80-ᓂᒃ ᐅᑭᐅᓛᑦ ᐅᖓᑖᓄᑦᓗ, ᐊᒻᒪᓗ
- ᐃᓐᓇᐃᑦ ᐅᓗᓇᐊᓇᕐᓂᒥᑦᑐᑦ ᓄᓇᖃᖅᑳᖅᑐᑦ ᓄᓇᓕᖏᓐᓂᑦ.

ᑲᓇᑕᒥᑦ ᐅᖃᐅᔾᔪᑎᒧᑦ ᐋᓐᓂᐊᖅᑕᐃᓕᒪᓂᕐᒧᑦ ᑲᐳᑎᓄᑦ ᑲᑎᒪᔨᕋᓛᑦ (NACI) ᐃᒪᓐᓈᖅᑐᐃᖃᑦᑕᖅᑐᑦ ᐊᑐᖅᑕᐅᕐᑯᐸᓗᑎᑦ ᐋᓐᓂᐊᖅᑕᐃᓕᒪᓂᕐᒧᑦ ᑲᐳᑏᑦ ᐅᕝᕙᓘᓐᓃᑦ ᓄᑖᑦ ᓈᒻᒪᒋᔭᐅᓵᖅᑐᓂᒃ ᑲᓇᑕᒥᐅᓄᑦ ᐊᑐᖅᑕᐅᓂᐊᕐᓗᑎᒃ, ᐃᓚᐅᐸᓗᓂ ᓄᕙᒡᔪᐊᕐᓇᖅ-19 ᐋᓐᓂᐊᓗᐊᖅᑕᐃᓕᔾᔪᑎᒧᑦ ᑲᐳᑏᑦ. ᑐᑭᓯᐅᒪᔾᔪᑎᒃᑲᓐᓂᕐᓂᒃ ᐱᔪᒪᒍᕕᑦ, ᐅᕗᖓᕐᓗᑎᑦ https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-prioritization-initial-doses-covid-19-vaccines.html

ᐃᓄᐃᑦ ᐋᓐᓂᐊᓕᖅᑐᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᐊᒻᒪᓗ ᖃᓄᐃᑦᑐᖕᓂᖅᓗᑎᒃ ᐃᑲᔪᖅᑕᐅᓂᖃᕈᖕᓇᖅᑐᑦ ᓱᓕ ᑲᐳᑎᒧᑦ. ᒫᓐᓇ ᓈᒻᒪᐅᑎᓂᒃ/ᑎᑎᖅᑲᓂᒃ ᐱᑕᖃᓗᐊᙱᑦᑐᖅ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐱᔭᐅᔾᔪᑎᓂᒃ ᐃᓄᖕᓂᒃ ᐋᓐᓂᐊᓕᕆᔩᖅᑐᓄᑦ ᑲᐱᔭᐅᖅᑳᖅᓗᑎᒃ ᐊᒻᒪᓗ ᖃᓄᐃᑦᑐᖕᓂᖅᓗᑎᒃ. ᐱᔾᔪᑎᒋᑉᓗᒍ ᑭᒡᓕᖃᖅᑐᓂᒃ ᑲᐳᑎᓂᒃ ᐱᔭᐅᓯᒪᔪᓂᒃ, NACI-ᑯᑦ ᐅᑕᖅᑭᕐᑯᐅᔪᑦ ᐱᖓᓱᓄᑦ ᑕᖅᑭᓄᑦ ᑲᐱᔭᐅᓂᐊᕐᓗᑎᒃ. ᐅᖃᖃᑎᒋᓗᒍ ᐋᓐᓂᐊᖃᖅᑕᐃᓕᒪᔪᓕᕆᔩᑦ ᖃᖓ ᐱᐅᓛᖑᓇᔭᕐᓂᖓ ᑲᐱᔭᐅᓂᐊᕐᓗᑎᑦ.

[1] ᐃᓄᓗᒃᑖᓄᑦ ᐋᓐᓂᐊᖃᖅᑕᐃᓕᒪᔪᓕᕆᔩᓂᕐᒧᑦ ᐱᔾᔪᔾᔨᔩᑦ ᑲᓇᑕᒥᑦ

ᓄᕙᒡᔪᐊᕐᓇᖅ-19 mRNA ᑲᑉᑏᑦ
Pfizer-BioNTech ᑲᑉᑎ ᐊᒻᒪᓗ ᒪᑑᓇ ᑲᑉᑎ

ᑐᑭᓯᐅᒪᔾᔪᑎᒃᑲᓐᓂᕐᓂᒃ ᐱᔪᒪᒍᕕᑦ ᒫᓂᑑᐸᒥᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐱᔭᐅᔪᓐᓇᖅᑐᓄᑦ, ᐅᑦᖓᕐᓗᑎᑦ https://www.gov.mb.ca/covid19/vaccine/eligibility-criteria.html.

ᐃᓄᐃᑦ ᐋᓐᓂᐊᕐᓂᖅᑲᖅᐸᑕ, ᓱᕐᓗ ᓇᑉᒍᐊᕐᓗᒃᑐᑦ ᐅᕝᕙᓘᓐᓃᑦ ᓴᔪᖅᑲᑦᑕᖅᑐᑦ, ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐱᔭᐅᔪᓐᓇᖅᐸᑦ?

NACI-ᑯᑦ ᑐᓂᔭᐅᔪᓐᓇᕐᓂᕋᐃᔪᑦ ᐃᓄᖕᓂᒃ ᐋᓐᓂᐊᕐᓂᖅᑲᖅᑐᓂᒃ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᑉᑎᒥᒃ ᕿᒥᕐᕈᖅᑎᖅᑲᖅᑲᖅᑎᓪᓗᒋᑦ ᐅᓗᕆᐊᓇᕐᓂᐅᔪᑦ ᐊᒻᒪᓗ ᐃᑲᔫᑏᑦ ᑲᐱᓯᔪᒧᑦ ᐅᕝᕙᓘᓐᓃᑦ ᐋᓐᓂᐊᖅᑕᐃᓕᒪᔪᓕᕆᔨᒧᑦ, ᐅᑯᓂᖕᒐᓪᓗ ᐃᓱᒪᒃᓴᖅᓯᐅᕈᑎᖅᑲᕐᓗᑎᒃ:

- ᐱᑕᖅᑲᓗᐊᖏᒃᑲᓗᐊᖅᑎᓪᓗᒍ ᐱᓐᓂᑯᓂᒃ ᐋᓐᓂᐊᖅᑲᕐᓗᓂ ᐃᖏᒃᑰᖓᔪᒃᑯᑦ ᐅᓗᕆᐊᓇᕐᓂᐅᖕᒪᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᑖᕐᓗᑎᒃ, ᐋᓐᓂᐊᕐᓂᖅᑲᕐᓗᓂ ᖃᐅᔨᓴᐅᓚᐅᖅᑐᖅ ᐃᖏᒃᑯᑦ ᐅᓗᕆᐊᓇᕐᓂᕐᒧᑦ ᐱᔾᔪᑕᐅᔪᑦ ᐋᓐᓂᐊᓕᕐᔪᐊᕐᓂᕐᒧᑦ ᐊᓯᖏᓐᓂᒃ ᐋᓐᓂᐊᕐᓂᐅᔪᓂᑦ (ᓱᕐᓗ, ᓄᕙᖕᓂᖅ).
- ᐱᑕᖅᑲᓗᐊᖏᑦᑐᖅ ᓈᓴᐅᑎᓂᒃ/ᑎᑎᖅᑲᓂᒃ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐱᔭᐅᔪᑦ ᐋᓐᓂᐊᕐᓂᖅᑲᖅᓱᑎᒃ.
- ᐃᓅᑉ ᖃᓄᐃᖓᓕᕈᓐᓇᕐᓂᖓ ᑲᑉᑎᓄᑦ ᐋᓐᓂᐊᕐᓂᓇᔭᖏᓐᓄᑦ ᐱᔾᔪᑎᖅᑲᖅᑐᑦ, ᐱᕙᓪᓕᐊᓂᖓᓄᑦ ᐋᓐᓂᐊᕐᓂᖅ ᐊᒻᒪᓗ ᐊᑐᖅᑕᐅᓂᖏᑦ ᐃᓗᐊᖅᓴᐅᑏᑦ.
- ᐃᓄᐃᑦ ᐋᓐᓂᐊᖅᑲᖅᑐᑦ ᖃᐅᔨᒪᔭᐅᔪᑦ ᐃᑲᔪᖅᑕᐅᓂᖅᑲᕐᓂᖏᓐᓄᑦ ᐊᓯᖏᓐᓂᒃ ᑲᑉᑎᓄᑦ (ᓱᕐᓗ, ᓄᓇᓗᐊᖅᑕᐃᓕᓂᕐᒧᑦ ᑲᑉᑎᒧᑦ).
- ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᑉᑎ ᐋᓐᓂᐊᕐᓂᕐᒥᒃ ᐱᒋᐊᓪᓕᒃᑎᑦᑎᔪᖕᓇᖅᑐᖅ ᑭᓯᐊᓂ ᑐᑭᓯᐅᒪᔾᔪᑎᑕᖅᑲᓂᖏᑦᑐᖅ ᑕᒪᑐᒧᖕᒐ.

ᐃᓄᐃᑦ ᐋᓐᓂᐊᖅᑲᖅᑐᑦ, ᓱᕐᓗ ᑳᓐᓯᖅᑲᖅᑐᑦ, ᐱᓕᕆᐊᖑᔪᓪᓗᓐᓃᑦ, ᓱᕐᓗ ᓴᖏᔪᓂᒃ ᐃᓗᐊᖅᓴᖅᑕᐅᖅᑕᐅᖅᑐᑦ, ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐱᔭᐅᔭᕆᐊᖅᑲᖅᐸᑦ?

NACI-ᑯᑦ ᑐᓂᔭᐅᔪᓐᓇᕐᓂᕋᐃᔪᑦ ᐃᓄᖕᓂᒃ ᐋᓐᓂᐊᕐᓂᖅᑲᖅᑐᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐱᔭᐅᔪᓐᓇᕐᓂᕋᐃᔪᑦ ᕿᒥᕐᕈᖅᑳᖅᑎᓪᓗᒋᑦ ᐅᓗᕆᐊᓇᕐᓂᐅᔪᑦ ᐊᒻᒪᓗ ᐃᑲᔫᑏᑦ ᕿᒥᕐᕈᖅᑎᖅᑳᖅᑎᓪᓗᒋᑦ ᐅᓗᕆᐊᓇᕐᓂᐅᔪᑦ ᐊᒻᒪᓗ ᐃᑲᔫᑏᑦ ᑲᐱᓯᔪᒧᑦ ᐅᕝᕙᓘᓐᓃᑦ ᐋᓐᓂᐊᖅᑕᐃᓕᒪᔪᓕᕆᔨᒧᑦ, ᐅᑯᓂᖕᒐᓪᓗ ᐃᓱᒪᒃᓴᖅᓯᐅᕈᑎᖅᑲᕐᓗᑎᒃ:

- ᐱᑕᖅᑲᓗᐊᖏᒃᑲᓗᐊᖅᑎᓪᓗᒍ ᐱᓐᓂᑯᓂᒃ ᐋᓐᓂᐊᖅᑕᐃᓕᒪᔾᔪᑎᖅᑲᖏᓐᓂᖅ ᐃᖏᒃᑰᖓᔪᒃᑯᑦ ᐅᓗᕆᐊᓇᕐᓂᐅᖕᒪᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᑖᕐᓗᑎᒃ, ᐋᓐᓂᐊᕐᓂᖅᑲᕐᓗᓂ ᖃᐅᔨᓴᐅᓚᐅᖅᑐᖅ ᐃᖏᒃᑯᑦ ᐅᓗᕆᐊᓇᕐᓂᕐᒧᑦ ᐱᔾᔪᑕᐅᔪᑦ ᐋᓐᓂᐊᓕᕐᔪᐊᕐᓂᕐᒧᑦ ᐊᓯᖏᓐᓂᒃ ᐋᓐᓂᐊᕐᓂᐅᔪᓂᑦ (ᓱᕐᓗ, ᓄᕙᖕᓂᖅ).
- ᐱᑕᖅᑲᓗᐊᖏᑦᑐᖅ ᓈᓴᐅᑎᓂᒃ/ᑎᑎᖅᑲᓂᒃ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐱᔭᐅᔪᑦ ᐋᓐᓂᐊᖅᑕᐃᓕᒪᔾᔪᑎᖅᖏᓐᓂᖅᑲᖅᑐᑦ.
- ᐃᓅᑉ ᖃᓄᐃᖓᓕᕈᓐᓇᕐᓂᖓ ᑲᑉᑎᓄᑦ ᐋᓐᓂᐊᕐᓂᓇᔭᖏᓐᓄᑦ ᐱᔾᔪᑎᖅᑲᖅᑐᑦ, ᐱᕙᓪᓕᐊᓂᖓᓄᑦ ᐋᓐᓂᐊᖅᑕᐃᓕᒪᔾᔪᑎᖅᖏᓐᓂᐅᔪᖅ ᐊᒻᒪᓗ ᐊᑐᖅᑕᐅᓂᖏᑦ ᐃᓗᐊᖅᓴᐅᑏᑦ.

ᐃᓄᐃᑦ ᐋᓐᓂᐊᖅᑲᖅᑐᑦ ᐊᑐᖅᑕᐅᖅᑐᑦ (HIV) ᐃᓱᒪᒋᔭᐅᔪᑦ ᐋᓐᓂᐊᖅᑕᐃᓕᒪᓂᕐᒧᑦ ᐊᔪᖏᓐᓂᖏᓐᓄᑦ ᑲᐱᔭᐅᔪᓐᓇᖅᑐᑦ; ᐅᖅᑲᖅᑎᒋᓗᒍ ᐋᓐᓂᐊᖅᑕᐃᓕᒪᔪᓕᕆᔨᑦ.

ᓄᑕᕋᒃᓴᓖᑦ ᐊᒻᒪᓗ/ᐅᕝᕙᓘᓐᓃᑦ ᐃᕕᐊᖏᖏᓐᓂᑦ ᐋᒫᒪᒃᑎᑦᑎᔪᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐱᔭᐅᔭᕆᐊᖅᑲᖅᐸᑦ?

NACI-ᑯᑦ ᐅᖅᑲᖅᑐᑦ ᐊᒻᒪᓗ ᑲᑐᔾᔨᖅᑲᑎᑖᑦ ᐊᕐᓇᐃᑦ ᓱᖕᒐᓕᕈᓐᓇᖅᑐᓕᕆᓂᖕᓄᑦ, (SOGC), ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐱᔭᐅᔪᓐᓇᖅᑐᑦ ᓄᑕᕋᒃᓴᓕᖕᓄᑦ ᐊᒻᒪᓗ/ᐅᕝᕙᓘᓐᓃᑦ ᐃᕕᐊᖏᖏᓐᓂᑦ ᐋᒫᒪᒃᑎᑦᑎᔪᓄᑦ ᕿᒥᕐᕈᖅᑎᖅᑲᖅᑲᖅᑎᓪᓗᒋᑦ ᐅᓗᕆᐊᓇᕐᓂᐅᔪᑦ ᐊᒻᒪᓗ ᐃᑲᔫᑏᑦ ᑲᐱᓯᔪᒧᑦ ᐅᕝᕙᓘᓐᓃᑦ ᐋᓐᓂᐊᖅᑕᐃᓕᒪᔪᓕᕆᔨᒧᑦ, ᐅᑯᓂᖕᒐᓪᓗ ᐃᓱᒪᒃᓴᖅᓯᐅᕈᑎᖅᑲᕐᓗᑎᒃ:

- ᐱᑕᖅᑲᓗᐊᖏᑦᑐᖅ ᐱᓐᓂᑯᓂᒃ ᓄᑕᕋᒃᓴᖅᑲᕐᓗᓂ ᐃᖏᒃᑰᖓᔪᒃᑯᑦ ᐅᓗᕆᐊᓇᕐᓂᐅᖕᒪᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᑖᕐᓗᑎᒃ. ᑭᓯᐊᓂ, ᐅᑭᐅᑖᑦ (≥ 35-ᓂᑦ), ᐳᕙᖏᓐᓄᑦ, ᖁᐃᓂᔪᓄᑦ, ᓱᐅᕋᐅᔾᔭᖅᑐᖅᑲᓗᐊᕐᓂᕐᒧᑦ, ᐆᒻᒪᑎᖏᑦ ᑎᒡᓕᒃᑖᖏᓐᓄᑦ ᐊᒻᒪᓗ ᐆᒪᑎᒃᑯᑦ ᐋᓐᓂᐊᕐᓂᖅᑲᖅᑐᑦ ᐃᖏᒃᑰᖓᔪᑦ ᐅᓗᕆᐊᓇᕐᓂᐅᔪᖅ ᐱᔾᔪᑕᐅᔪᓂᒃ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒥᒃ ᐋᓐᓂᐊᓕᕐᔪᐊᕐᓂᓗᓂ.
- ᓈᓴᐅᑎᓂᒃ/ᑎᑎᖅᑲᓂᒃ ᐱᑕᖅᑳᓂᖏᑦᑐᖅ ᓄᕙᒡᔪᐊᕐᓇᖅ-19 ᑲᑉᑎᒧᑦ ᓄᑕᕋᒃᓴᓕᖕᓄᑦ ᐊᒻᒪᓗ/ᐅᕝᕙᓘᓐᓃᑦ ᐃᕕᐊᖏᖏᓐᓂᑦ ᐋᒫᒪᒃᑎᑦᑎᔪᓄᑦ.
- ᐱᓐᓂᑯᑕᖅᑲᖏᑦᑐᖅ ᖃᐅᔨᓂᐊᕐᓂᓂ ᑲᑉᑏᑦ ᐅᓗᕆᐊᓇᕐᓂᖅᑲᕐᒪᖔᑕ ᐅᕝᕙᓘᓐᓃᑦ ᐃᑲᔪᐃᓂᕐᑲᕐᒪᖔᑕ ᓄᑕᕋᒃᓴᒧᑦ ᐊᒻᒪᓗ/ᐅᕝᕙᓘᓐᓃᑦ ᐃᕕᐊᖏᖏᑦ ᐋᒫᒪᒃᑐᑦ ᓄᑕᕋᓪᓗᒧᑦ.
- ᒫᓇᐅᔪᖅ ᐱᓐᓂᑯᑕᖅᑲᖏᑦᑐᖅ ᒪᓕᒃᑕᐅᔪᒃᓴᓂᒃ ᐊᑯᓐᓂᖏᓐᓂᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐱᔭᐅᔾᔪᑎᓄᑦ ᐊᒻᒪᓗ ᓄᑕᕋᒃᓴᖅᑖᕐᓂᕐᒧᑦ. NACI ᓄᑕᕋᒃᓴᖅᑖᕐᑯᔨᖅᑐᑦ 28 ᐅᑉᓗᓂᑦ ᐅᖓᑖᓄᑦᓗᓐᓃᑦ ᐱᐊᓂᒃᑕᐅᖅᑳᖅᑎᓪᓗᒋᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐱᔭᐅᔾᔪᑎᓗᒃᑖᑦ.

ᐋᓐᓂᐊᕐᓂᖅᑲᖅᓗᓂ ᑎᑎᕋᖅᓯᒪᖏᑦᑐᑦ ᖁᓛᓂᑦ (ᓱᕐᓗ, ᐆᒻᒪᑎ ᐊᔪᓕᖅᑐᖅ, ᑎᖑᒃᑯᑦ ᐋᓐᓂᐊᖅᑖᕐᓂᕐᒥᒃ, ᑕᖅᑐᒃᑯᓪᓗ ᐋᓐᓂᐊᖅᑖᕐᓂᕐᒥᒃ) ᑐᑭᖅᖏᑦᑐᖅ ᑲᑉᑎᒥᒃ ᐱᔭᕆᐊᖅᖏᓐᓇᕕᑦ. ᐅᖅᑲᖅᑎᒋᓗᒍ ᐋᓐᓂᐊᖅᑕᐃᓕᒪᔪᓕᕆᔨᑦ ᐊᐱᖅᑯᑎᒃᓴᖅᑭᕕᑦ.

ᓱᕐᖅ ᐱᖏᓪᓕ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐱᔭᐅᔾᔪᑎᒥᒃ?

ᓄᑕᕋᓛᑦ ᐊᒻᒪᓗ ᓄᑕᖅᑲᐃᑦ ᐅᑭᐅᓛᑦ 16 ᑐᖕᒐᓂᑦ ᑐᓂᔭᐅᔭᕆᐊᖅᖏᑦᑐᑦ Pfizer-BioNTech ᑲᑉᑎᒥᑦ. ᐃᓄᐃᑦ ᐅᑭᐅᓛᑦ 18 ᑐᖕᒐᓂᑦ ᑐᓂᔭᐅᔭᕆᐊᖅᖏᑦᑐᑦ ᒪᑑᓇ ᑲᑉᑎᒥᒃ.

ᒫᓇ ᓈᓴᐅᑎᓂᒃ/ᑎᑎᖅᑲᓂᒃ ᐱᑕᖅᖏᑦᑐᖅ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐱᔭᐅᔾᔪᑎᓂᒃ ᓄᑕᖅᑲᓄᑦ ᐅᑭᐅᓛᑦ 12 ᑐᖕᒐᓂᑦ, ᐊᒻᒪᓗ ᑭᒡᓕᖅᑲᖅᑐᓂᒃ ᓈᓴᐅᑏᑦ/ᑎᑎᖅᑲᐃᑦ ᑕᐃᒪᐅᔾᔪᑎᒃ Pfizer-BioNTech ᑲᑉᑎᓄᑦ 12-ᓂᒃ 15-ᓄᑦ ᐅᑭᐅᓕᖕᓄᑦ. NACI ᒪᓕᒃᓗᒋᑦ, Pfizer-BioNTech ᑲᑉᑏᑦ ᑐᓂᔭᐅᖅᑕᕋᓇᐊᖅᖏᑦᑐᑦ ᓄᑕᖅᑲᓄᑦ ᐅᑭᐅᓛᑦ 12-ᓂᒃ 15-ᓄᑦ. ᐃᓗᐊᖅᓴᐃᔨᑦ ᐆᒃᑐᕋᐃᓂᖏᑦ ᐊᒻᒪᓗ ᑭᖑᓂᐊᒍᑦ ᒪᓂᒪᓕᖅᑎᑕᐅᖅᑳᖅᑎᓪᓗᒋᑦ ᖃᐅᔨᓴᐃᓐᑦ ᑲᔪᓯᔪᑦ ᐊᒻᒪᓗ NACI-ᑯᑦ ᖃᐅᔨᓴᐃᔪᑦ ᐱᓐᓂᑯᓂᒃ ᐱᕙᓪᓕᐊᑎᓪᓗᒋᑦ.

ᓄᕙᒡᔪᐊᕐᓇᖅ-19 mRNA ᑲᐳᑏᑦ
Pfizer-BioNTech ᑲᐳᑎ ᐊᒻᒪᓗ ᒪᑑᓇ ᑲᐳᑎ

ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐳᑎ ᑐᓂᔭᐅᔭᕆᐊᖅᑕᕐᑐᖅ ᐃᓄᖕᓄᑦ ᐊᓗᔾᔨᒃᑲᑦᑕᖅᑐᓄᑦ ᑲᐳᑎᒦᑦᑐᓄᑦ ᐃᓚᒋᔭᐅᔪᓄᑦᓗᓐᓂᑦ ᑲᐳᑎᒧᑦ, ᐅᕝᕙᓘᓐᓂᑦ ᐊᓗᔾᔨᒃᑲᔪᐊᖅᓯᒪᒍᕕᑦ ᓯᕗᑦᓕᖅᐸᒥᒃ ᑲᐱᔭᐅᖅᑳᖅᑎᑦᓗᑎᑦ. ᐊᓗᔾᔨᒃᑐᑦ ᐅᓗᕆᐊᓇᕈᓐᓇᖅᑐᖅ ᐃᓅᑉ ᐃᓅᓯᖕᒐᓄᑦ. ᑐᑭᓯᐅᒪᔾᔪᑎᓂᒃ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐳᑎᐅᑉ ᐃᓗᐊᓃᑦᑐᓄᑦ ᒥᒃᓴᓄᑦ ᐱᔪᒪᕕᑦ, ᕿᒥᕐᕈᓗᒍ ᑲᐳᑎᓕᐅᖅᑑᑉ ᐅᖃᓕᒫᖕᒋᑦ, ᒪᓂᒪᔪᖅ ᐅᕙᓂ: www.manitoba.ca/vaccine ᐅᕝᕙᓘᓐᓂᑦ ᐅᖃᑦᓚᖃᑎᒋᓗᒍ ᐊᓐᓂᐊᖃᑦᑕᐃᓕᒪᔪᓕᓇᔨᑦ.

Polyethylene glycol (PEG) ᐃᓚᒋᔭᐅᔪᖅ ᒪᑑᓇ ᑲᐳᑎᓄᑦ ᐊᒻᒪᓗ ᐊᓗᔾᔨᒃᑕᐅᔪᖕᓇᖅᑐᑦ ᖃᐅᔨᒪᐅᔪᑦ, ᐃᓚᐅᑉᓗᑎᒃ ᐱᒻᒪᕆᐅᔪᑦ ᐊᓗᔾᔨᒃᒧᑦ ᐱᔪᓂᒃ. Polyethylene glycol ᑕᐃᒪᐅᖃᑦᑕᖅᑐᑦ ᐊᒥᓱᓂᑦ ᐃᓚᐅᑉᓗᑎᒃ ᐃᓄᐊᓗᐊᓕᕆᓂᕐᒧᑦ ᐸᕐᓇᐃᓂᕐᒧᑦ ᑕᑯᔭᐅᓂᐊᕐᓗᓂ ᐃᓇᓗᐊᑎᑦ, ᐊᓇᕐᒥᒃ ᐊᕿᒡᓕᑎᒋᑎᓂᑦ, ᓄᕙᓯᐅᑎᓂᑦ, ᐱᐅᓴᐅᑎᓂᑦ, ᐃᔾᒧᐊᓱᑦ ᑕᐅᑐᑦᑎᐊᒋᑎᓂᑦ, ᐅᕕᓂᒃᓯᐅᑎᓂᑦ, ᐊᒻᒪᓗ ᐃᓚᓕᐅᑎᔭᐅᖃᑦᑕᖅᑐᓂ ᐃᓚᖏᓄᑦ ᓂᕿᓕᐊᓄᑦ ᐊᒻᒪᓗ ᓂᐅᖅᑲᒐᒃᓴᓄᑦ. ᐊᓗᔾᔨᒃᑯᕕᑦ Polyethylene glycol-ᒧᑦ (PEG) ᐅᕝᕙᓘᓐᓂᑦ polysorbate-ᒧᑦ, ᖃᓄᑎᒋᐅᒐᓗᐊᖅᐸᑦ ᐊᓗᔾᔨᒃᓂᓇᔭᐃᑦ, ᐅᖃᐅᑎᓗᒍ ᐋᓂᐊᖃᑦᑕᐃᓕᒪᔪᓕᓇᔨᑦ ᑲᐱᔭᐅᓂᐊᓴᖅᑎᓪᓗᑎᑦ.

ᐊᓗᔾᔨᒃᔪᐊᖃᑦᑕᖅᓯᒪᒍᕕᑦ ᓂᕿᓄᑦ, ᐃᓗᐊᖅᓴᐅᑎᓄᑦ, ᐊᕙᑎᒧᑦ ᐊᑐᖅᑕᐅᖃᑦᑕᖅᑐᓂᑦ ᐊᓯᖏᓐᓄᑦᓗᓐᓂᑦ ᐊᓗᔾᔨᒃᓇᐅᑎᓄᑦ, ᐅᖃᖃᑎᒋᓗᒍ ᐋᓂᐊᖃᑦᑕᐃᓕᒪᔪᓕᓇᔨᑦ ᑲᐱᔭᐅᓂᐊᓴᖅᑎᓪᓗᑎᑦ.

NACl-ᑯᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19 ᐋᓂᐊᓗᐊᖅᑕᐃᓕᔾᔪᑎᒧᑦ ᑲᐳᑎᓂᒃ ᑐᓂᔭᐅᔭᕆᐊᖅᑕᖅᑐᑦ ᐊᑕᐅᑦᑎᒃᑰᕐᓗᑦ ᐊᓯᖏᓐᓄᑦ ᑲᐱᔭᐅᔪᑎᓄᑦ (ᐆᒪᔪᖅ ᐆᒪᒪᓂᖅᑐᕐᓗᓐᓂᑦ) ᑲᐳᑎᓂᒃ. ᐅᑕᖅᑭᓗᑎᑦ 14 ᐅᑉᓗᓂᑦ ᑭᖑᓂᐊᒍᑦ ᓱᓇᑐᐃᓐᓇᒧᑦ ᑲᐱᔭᐅᓯᒪᒍᕕᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐱᔭᐅᓂᐊᕐᓗᑎᑦ. ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐳᑎᓗᒃᑖᓄᑦ ᑲᐱᔭᐅᕋᓂᒃᑯᕕᑦ, ᐅᑕᖅᑭᓗᑎᑦ 28 ᐅᑉᓗᓂᒃ ᐊᓯᐊᓂᒃ ᑲᐱᔭᐅᓂᐊᕐᓗᑎᑦ, ᑭᓯᐊᓂ ᑲᐳᑎ ᐱᔭᐅᑲᐅᑎᒋᔭᕆᐊᖅᑲᖅᐸᑦ ᐋᓂᐊᖅᑎᓪᓗᑎᑦ ᓱᕐᓗ ᑎᖑᒃᑯᑦ Hepatitis B-ᒥᒃ. ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐱᔭᐅᕋᓂᒃᓯᒪᒍᕕᑦ, ᐱᐊᓂᒡᓗᑎᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐳᑎᓗᒃᑖᑦ.

ᐆᓇᕈᕕᑦ ᐅᕝᕙᓘᓐᓂᑦ ᐋᓂᐊᕈᕕᑦ ᐱᔾᔪᑕᐅᔪᖕᓇᖅᑐᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᖃᕐᓂᕐᒧᑦ, ᐋᓂᐊᖅᑎᓪᓗᑎᑦ ᑲᐱᔭᐅᔭᕆᐊᖅᑕᖅᑐᑎᑦ. ᐅᖃᖃᑎᒋᓗᒍ ᐋᓂᐊᖃᑦᑕᐃᓕᒪᔪᓕᓇᔨᑦ ᐋᓂᐊᕐᓂᕕᑦ ᒥᒃᓴᓄᑦ ᐊᒻᒪᓗ ᐆᑐᕋᖅᑕᐅᓂᐊᕐᓗᑎᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᖃᕐᒪᖔᖅᐱᑦ. ᐋᓂᐊᖃᑦᑕᐃᓕᒪᔪᓕᓇᔨᑦ ᐅᖃᐅᑎᓂᐊᖅᑖᑎᑦ ᖃᖑᒃᑯᑦ ᑲᐱᔭᐅᔪᖕᓇᕐᓂᐊᕐᒪᖔᖅᐱᑦ.

ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐱᔭᐅᓗᓂ ᐋᓂᐊᕐᓂᑦ ᖃᓄᐃᖕᒐᓕᖅᑎᑦᑎᓂᐅᔪᖕᓇᖅᑐᑦ

ᖃᓄᖕᒋᖕᒐᓕᖅᑎᑦᑎᓂᐅᔪᖕᓇᖅᑐᑦ ᖃᐅᔨᔭᐅᔪᑦ ᐆᒃᑐᕋᐃᓂᖃᖅᑎᓪᓗᑎᑦ ᐊᔾᔨᑦᒪᒋᔭᖏᑦ ᐊᓯᖏᓐᓄᑦ ᑲᐳᑎᓄᑦ, ᖃᓄᐃᓗᐊᓚᐅᖏᑦᑐᑦ ᕿᑎᐊᓂᖕᒐᑉᓗᑎᒃᓗᓐᓂᑦ, ᐊᒻᒪᓗ ᐱᑕᖃᕈᖕᓂᖅᓗᑎᒃ ᖃᑉᓯᐊᕐᔪᐃᑦ ᐅᑉᓗᐃᑦ ᐊᓂᒍᖅᑎᓪᓗᑎᑦ ᑲᐱᔭᐅᖕᒪᑕ. ᐃᓚᐅᔪᑦ ᐋᓂᐊᕐᓂᖅ, ᐊᐅᑉᓗᒃᓯᓂᖅ ᐊᒻᒪᓗ ᐳᕕᓕᕐᓂᖅ ᑲᐱᔭᐅᕝᕕᖕᒐᓂᑦ, ᐃᒃᑮᓕᖅᓯᒪᓂᖅ, ᑕᖃᓯᒪᓂᖅ ᐊᒻᒪᓗ ᐆᓇᖅᓯᓯᒪᓂᖅ, ᓂᐊᕐᑯᙳᓂᖅ, ᓂᕿᒃᑯᑦ ᓇᑉᐊᒃᑯᓪᓗ ᐋᓂᐊᕐᓂᖅ ᐊᒻᒪᓗ ᒥᓇᐊᖑᓂᖅ ᐊᒻᒪᓗ ᒥᓇᐊᑲᑦᓂᖅ. ᐃᓗᐊᖅᓴᐅᑎᑖᕐᕕᖕᒥᑦ ᓂᐊᕐᑯᙳᓂᕐᒧᑦ ᐃᓗᐊᖅᓴᐅᑎᑦ (ᓱᕐᓗ ᑕᐃᓕᓈᑦ® ᐅᕝᕙᓘᓐᓂᑦ ᐊᓯᖏᑦ (ᐋᑦᕕᐅᑦ®) ᐃᑲᔪᖃᑦᑕᖅᑐᑦ ᐋᓂᐊᕐᓂᕐᒧᑦ (ᐋᓂᐊᓂᕐᒥᒃ ᐃᒃᐱᒍᓱᖕᓂᕐᒧᑦ, ᓂᐊᕐᑯᙳᓂᕐᒧᑦ), ᑕᐃᒪᐅᒃᑕᑦ **ᑭᖑᓂᐊᒍᑦ ᑲᐱᔭᐅᖃᑲᖅᑎᓪᓗᑎᑦ.**

ᑕᐃᒪᓐᓇᐃᒐᔪᒃᑐᑦ ᑲᐱᔭᐅᖅᑲᖅᓱᓂ ᐊᒻᒪᓗ ᐅᓗᕆᐊᓇᖕᒋᑦᑐᑦ ᐋᓂᐊᖃᖅᑕᐃᓕᒪᓂᕐᓄᑦ.

ᑎᑎᕋᖅᓯᒪᔪᑦ ᖃᓄᐃᑦᑐᓂᒃ ᐋᓂᐊᓕᕈᑕᐅᔪᓄᑦ ᕿᒥᕐᕈᓗᒍ ᑲᐳᑎᓕᐅᖅᑑᑉ ᐅᕐᑲᓕᒫᖕᒐ, ᒪᓂᒪᔪᖅ ᐅᕙᓂ www.manitoba.ca/vaccine ᐅᕝᕙᓘᓐᓂᑦ ᐋᓂᐊᖃᖅᑕᐃᓕᒪᔪᓕᓇᔨᖕᓄᑦ ᐅᖃᕐᑲᑎᖃᕐᓗᑎᑦ.

ᑕᒪᕐᒥᓗᒃᑖᖅ ᑲᐳᑏᑦ, ᖃᓄᐃᖕᒐᓕᖅᑎᑦᑎᓂᖃᕐᓂᖅᓴᐅᔪᑦ ᓱᕐᓗ ᐊᓗᔾᔨᒃᑎᑦᑎᔪᑦ ᑕᐃᒪᐅᔪᖕᓇᖅᑐᑦ. ᑭᓯᐊᓂ, ᑕᐃᒪᓐᓇᐃᒐᔪᖕᒋᑦᑐᑦ.

ᑲᓇᑕᒥᑦ ᐋᓂᐊᖃᖅᑕᐃᓕᒪᔪᓕᓇᔨᒃᑯᑦ ᐊᖏᔪᒥᒃ ᓱᓇᑐᐃᓐᓇᓕᓇᓂᒃᑯᑦ ᕿᒥᕐᕈᓂᖃᓚᐅᖅᑐᑦ ᒪᓂᒪᔪᓂᒃ ᐃᓗᐊᖅᓴᐃᓂᕐᒧᑦ ᐱᓐᓂᑯᓂᒃ ᖃᐅᔨᓴᕐᓂᐊᕐᓗᑎᑦ ᐅᓗᕆᐊᓇᖕᒋᓐᓂᖕᒋᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19 mRNA ᑲᐳᑏᑦ. ᑲᓇᑕᒥᑦ ᐋᓂᐊᖃᖅᑕᐃᓕᒪᔪᓕᓇᔨᒃᑯᑦ ᖃᐅᔨᓚᐅᖕᒋᑦᑐᑦ ᐊᖏᔪᓂᒃ ᐅᓗᕆᐊᓇᕐᓂᖕᒋᓐᓄᑦ ᐃᓱᒪᓗᑎᓂᒃ.

ᑲᓇᑕᒥᑦ ᐋᓂᐊᖃᖅᑕᐃᓕᒪᔪᓕᓇᔨᒃᑯᑦ ᖃᐅᔨᓴᐃᖕᒋᓐᓇᕐᓂᐊᖅᑐᑦ ᐊᑐᖅᑕᐅᓕᖅᑲᖅᑎᓪᓗᑎᑦ, ᖃᐅᔨᓴᐃᒃᑲᓐᓂᕐᓗᑎᒃ ᐊᒻᒪᓗ ᐃᓗᐊᖅᓴᐅᑎᒋᓗᒍ ᐋᒃᑐᕋᐅᑎᒋᓗᒍ ᖃᐃᔾᔨᓂᐊᕐᓗᑎᒃ ᐅᓗᕆᐊᓇᖅᑐᓄᑦ ᓇᓗᓇᐃᖅᓯᔾᔪᑎᓂᒃ ᐱᐊᓛᓚᒃᑯᑦ.

ᐱᒻᒪᕆᐅᔪᖅ ᑲᐱᔭᐅᕝᕕᐅᖅᑲᐅᔪᒦᓪᓗᓂ ᑲᐱᔭᐅᕋᓂᒃᐸᑕ 15 ᒥᓂᑦᓂᑦ (ᐊᑯᓂᐅᓂᖅᓴᕐᓗᓐᓂᑦ ᐃᓚᖏᓐᓄᑦ ᐃᓄᖕᓄᑦ, ᐃᓚᐅᑉᓗᑎᒃ ᐊᓗᔾᔨᒃᑲᑦᑕᖅᓯᒪᔪᑦ) ᐊᓗᔾᔨᒃᒐᕐᓂᖅᐸᑕ. ᐅᖏᓚᓕᕐᓗᑎᒃ, ᐊᓂᖅᓴᕐᑎᐊᕐᓂᖅ ᐊᔪᓕᕐᓗᑎᒃ, ᐅᕝᕙᓘᓐᓂᑦ ᐳᕕᓕᕐᓗᑎᒃ ᐃᒻᒋᐊᖏᑦᑎᒍᑦ, ᐅᖃᖕᒐᒍᑦ ᖃᓂᐊᒍᓪᓗᓐᓂᑦ. ᑕᐃᒪᓐᓇᐃᑦᑐᓐᓇᖅᑐᑦ ᐊᑕᐅᓯᖅ ᐃᑲᕐᕋᒧᑦ ᑎᑭᓪᓗᒍ ᑲᐱᔭᐅᕋᓂᒃᓯᒪᓕᖅᑎᓪᓗᒍ. ᑕᐃᒪᓐᓇᐃᓕᒍᕕᑦ ᐊᓂᓯᒪᓕᕐᓗᑎᑦ ᑲᐱᔭᐅᕝᕕᑎᖅᑲᐅᔭᕐᓂᑦ, **ᐅᖃᓗᒃᓗᑎᑦ 911-ᒧᑦ ᐅᕝᕙᓘᓐᓂᑦ ᖃᓂᓛᕐᒧᑦ ᑐᐊᕕᓇᖅᑐᒃᑯᓐᓄᐊᕐᓗᑎᑦ ᐋᓂᐊᕐᕕᖕᒧᓪᓗᓐᓂᑦ ᑲᒪᒋᔭᐅᑲᐅᑎᒋᓂᐊᕐᓗᑎᑦ.**

ᐅᖃᐅᓯᕆᓗᒋᑦ ᐱᒻᒪᕆᐅᔪᑦ ᐅᕝᕙᓘᓐᓂᑦ ᓂᕆᐅᓇᖕᒋᑦᑐᑦ ᖃᓄᐃᓕᖕᒐᓕᕈᑦᑎᑦ ᐋᓂᐊᖃᑦᑕᐃᓕᒪᔪᓕᓇᔨᓄᑦ, ᐅᖃᓗᒃᕕᒋᓗᑏᑦᓪᓗᓐᓂᑦ ᐅᑯᐊ: ᐋᓂᐊᖃᑦᑕᐃᓕᒪᔪᓕᓇᔨᓄᐊᕈᑏᑦ Health Links-Info Santé at 204-788-8200 or 1-888-315-9257 (ᐊᑭᖃᖕᒋᑦᑐᖅ ᐅᖃᓗᑎ).

ᐸᕐᓇᒃᐸᓪᓕᐊᓂᖅ ᑲᐱᔭᐅᓂᐊᕐᓗᑎᑦ

ᒪᓕᖕᓂᐊᖅᐸᑎᑦ ᓇᓗᓇᐃᒃᑰᑎᑦ ᖃᓄᐃᓕᐅᕆᐊᖃᕐᓂᕐᒧᑦ ᑲᐱᔭᐅᕝᕕᖕᒥᑦ (ᓱᕐᓗ, ᒪᕐᕉᒃ ᒦᑕᓂᒃ ᐅᖓᓯᒃᑎᒋᔭᕆᐊᖃᕐᓂᖅ ᐊᓯᖏᓐᓄᑦ ᐃᓄᖕᓂᑦ), ᐊᒻᒪᓗ ᐊᐃᓯᒪᓗᑎᑦ ᐋᓂᐊᕈᕕᑦ.

- ᐊᐃᑭᑦᑐᒥᒃ ᐊᑎᑎᓯᒪᓗᑎᑦ ᐊᐃᓕᖕᓂᓪᓗᓐᓂᑦ ᑕᓕᖕᓂᑦ ᓴᖅᑭᑦᑎᑲᐅᑎᒋᔭᖕᓇᖅᑐᒥᒃ.
- ᓂᕆᑦᑎᐊᖅᓯᒪᓗᑎᑦ ᑕᐃᑲᓂ ᐅᑉᓗᕐᒥᑦ.
- ᓇᒃᓴᕐᓗᒍ ᐊᒻᒪᓗ ᐊᑐᕐᓗᒍ ᑮᓇᕐᒧᑦ ᒪᒃᐱᒐᐃᑦ.
- ᑭᓇᐅᓂᕐᓄᑦ ᓇᓗᓇᐃᒃᑯᑎᓕᒃᕐᓗᑎᑦ ᐱᔭᐅᔭᕆᐊᓕᖕᓂᒃ ᑲᐱᔭᐅᕝᕕᖕᒥᑦ, ᓱᕐᓗ ᒫᓂᑉᐳᒧᑦ ᐋᓂᐊᖃᑦᑕᐃᓕᒪᐅᔪᓕᓇᔨᒃᑯᓐᓄᑦ ᓇᑦᓕᐅᒃᑯᒫᕐᑲᕈᑏᑦ.
- ᑲᐱᔭᐅᖃᑦᑕᕐᓂᖕᓄᑦ ᑎᑎᖅᑲᐅᑏᑦ ᓇᒃᓴᕐᓗᒍ.

ᑖᑉᑯᐊ ᑐᑭᓯᐅᒪᔾᔪᑏᑦ ᐊᓯᐊᙳᑐᐃᓐᓇᓇᐊᖃᖅᑐᑦ. ᓇᓚᐅᑦᑎᓯᒪᔪᖅ ᓴᓄᐊᓇ 13, 2021-ᒥᑦ.

ᓄᕙᒡᔪᐊᕐᓇᖅ-19 mRNA ᑲᔾᑏᑦ
Pfizer-BioNTech ᑲᔾᑎ ᐊᒻᒪᓗ ᒪᔅᑐᓇ ᑲᔾᑎ

ᑲᐱᔭᐅᕋᓂᒃᑯᑦ, ᑕᐅᑐᒐᖅᑲᐃᓐᓇᕐᓗᑎᑦ ᐱᒻᒪᕆᐅᔪᑦ ᓯᐊᒻᒪᒃᑎᑦᑎᑦᑕᐃᓕᓂᕐᒧᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒥᑦ. ᑐᑭᓯᐅᒪᔾᔪᑎᒃᑲᓐᓂᕐᓂᒃ ᐱᔪᒪᒍᕕᑦ ᐅᕗᖓᕐᓗᑎᑦ https://www.gov.mb.ca/covid19/updates/prepareandprevent.html#fundamentals.

ᑎᑎᖅᑲᐅᑏᑦ ᒥᐊᓂᕆᔭᐅᓂᕐᒧᑦ

ᑲᐱᔭᐅᔾᔪᑎᓗᒃᑖᑦ, ᐃᓚᐅᑉᓗᓂ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧᑦ ᑲᐱᔭᐅᔾᔪᑎ, ᑎᑎᕋᖅᓯᒪᔪᑦ ᑲᐱᔭᐅᔾᔪᑎᖕᓄᑦ ᑎᑎᖅᑲᐅᑎᖕᓂᑦ ᒫᓂᑑᐸᒥᑦ ᑲᐱᔭᐅᔪᓄᑦ ᑎᑎᕋᖅᓯᒪᔪᓂᑦ. ᑎᑎᕋᖅᓯᒪᔪᓂᑦ:

- ᐋᓐᓂᐊᖅᑲᖅᑕᐃᓕᒪᔪᓕᕆᔨᐅᔪᑦ ᓇᓂᓯᔪᖕᓇᖅᑐᑦ ᓇᓕᖕᒋᓐᓂᒃ ᑲᐱᔭᐅᓯᒪᓂᕐᓂᑦ (ᐅᕝᕙᓘᓐᓃᑦ ᐃᓄᐃᑦ ᑲᒪᒋᔭᑎᑦ) ᐱᓚᐅᖅᑕᑎᑦ ᐅᕝᕙᓘᓐᓃᑦ ᑲᐱᔭᐅᔾᔪᑎᒋᔭᕆᐊᖅᑲᖅᑕᑎᑦ.
- ᐊᑐᖅᑕᐅᔪᖕᓇᖅᑐᑦ ᐋᖅᑭᒃᓯᓂᐊᕐᓗᑎᒃ ᑲᐱᔭᐅᔾᔪᑎᒋᔭᕐᓄᑦ ᑎᑎᖅᑲᐅᑎᓂᒃ ᐅᕝᕙᓘᓐᓃᑦ ᖃᐅᔨᑎᑦᓗᑎᑦ ᐅᕝᕙᓘᓐᓃᑦ ᐋᓐᓂᐊᖅᑲᖅᑕᐃᓕᒪᔪᓕᕆᔨᑦ ᓇᓕᑐᐃᓐᓇᖕᒋᓐᓄᑦ ᑲᐱᔭᐅᓯᒪᙱᒃᑯᕕᑦ.
- ᒫᓂᑑᐸ ᐋᓐᓂᐊᖅᑲᖅᑕᐃᓕᒪᔪᓕᕆᔨᒃᑯᑦ, ᐃᓐᓇᐃᑦ ᐊᒻᒪᓗ ᐊᐅᓚᑲᑕᒡᓗᑎᒃ ᐃᓅᓂᖅ ᑲᒪᔨᒃᑯᑦ ᐊᒻᒪᓗ ᐋᓐᓂᐊᖅᑲᖅᑕᐃᓕᒪᔪᓕᕆᔨᑦ ᖃᐅᔨᓴᕐᓗᑎᒃ ᖃᓄᖅ ᑲᐳᑏᑦ ᐃᑲᔪᕐᓂᖅᑲᕐᒪᖔᑕ ᐋᓐᓂᐊᖅᑕᐃᓕᓂᕐᒧᑦ.

ᓇᖕᒥᓂᕐᒧᑦ ᐋᓐᓂᐊᖅᑲᖅᑕᐃᓕᒪᓂᕐᒧᑦ ᑐᑭᓯᐅᒪᔾᔪᑎᓄᑦ ᐱᕐᑯᔭᖅ ᒥᐊᓂᖅᓯᔪᖅ ᑐᑭᓯᐅᒪᔾᔪᑎᓂᒃ ᐃᓕᖕᓅᖓᔪᓂᒃ ᐊᒻᒪᓗ/ᐅᕝᕙᓘᓐᓃᑦ ᑭᓇᑐᐃᓐᓇᕐᒥᒃ ᐃᓄᖕᒥᒃ ᑲᒪᒋᔭᕐᓂᑦ. ᓂᕈᐊᕈᖕᓇᖅᑐᑎᑦ ᐃᓕᖕᓄᑦ ᐋᓐᓂᐊᖅᑲᖅᑕᐃᓕᒪᓂᕐᒧᑦ ᑐᑭᓯᐅᒪᔾᔪᑏᑦ ᑕᑯᔭᐅᕐᑯᙱᒃᑯᒃᑎᒃ ᐋᓐᓂᐊᖅᑲᖅᑕᐃᓕᒪᔪᓕᕆᔨᐅᔪᓄᑦ. ᑐᑭᓯᐅᒪᔾᔪᑎᒃᑲᓐᓂᕐᓂᒃ ᐱᔪᒪᒍᕕᑦ, ᖃᐅᔨᒋᐊᕐᕕᒋᓗᒋᑦ ᓄᓇᓕᖕᒥᑦ ᐋᓐᓂᐊᕐᕕᒃ ᐅᖃᖃᑎᖃᕐᓗᑎᓪᓘᓐᓃᑦ ᐋᓐᓂᐊᖅᑲᖅᑕᐃᓕᒪᔪᓕᕆᔨᒥᒃ.

ᑐᑭᓯᐅᒪᔾᔪᑎᓂᒃ ᐱᔪᒪᒍᕕᑦ ᑲᐱᔭᐅᔾᔪᑏᑦ ᒥᒃᓵᓄᑦ ᐃᒡᕕᑦ ᑲᒪᒋᔭᑎᓪᓘᓐᓃᑦ ᐱᓯᒪᔭᖕᒋᓐᓂᑦ, ᖃᐅᔨᒋᐊᕐᓗᒋᑦ ᐋᓐᓂᐊᖅᑲᖅᑕᐃᓕᒪᔪᓕᕆᔨᒋᔭᐃᑦ. ᖃᐅᔨᒋᐊᕐᓗᒋᑦ ᐋᓐᓂᐊᖅᑲᖅᑕᐃᓕᒪᔪᓕᕆᔨᒃᑯᑦ ᑎᑎᕋᕐᕕᖓᑦ ᐊᔾᔨᖓᓂᒃ ᑲᐱᔭᐅᖅᑲᑦᑕᕐᓂᖕᓄᑦ ᑎᑎᖅᑲᐅᑎᓂᒃ ᐱᔪᒪᒍᕕᑦ.

ᑎᑎᕋᖅᓯᒪᔪᓂᒃ ᐱᔪᒪᒍᕕᑦ ᐋᓐᓂᐊᖅᑲᖅᑕᐃᓕᒪᔪᓕᕆᔨᒃᑯᑦ ᑎᑎᕋᕐᕕᖕᒋᓐᓄᑦ, ᐅᕗᖓᕐᓗᑎᑦ: www.manitoba.ca/health/publichealth/offices.html.

ᑐᑭᓯᐅᒪᔾᔪᑎᒃᑲᓐᓂᕐᓄᑦ

ᑐᑭᓯᐅᒪᔾᔪᑎᒃᑲᓐᓂᕐᓂᒃ ᐱᔪᒪᒍᕕᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19 ᒥᒃᓵᓄᑦ ᐅᕝᕙᓘᓐᓃᑦ ᓄᕙᒡᔪᐊᕐᓇᖅ-19 ᑲᔾᑎᑦ ᒥᒃᓵᓄᑦ, ᐅᖃᑦᓚᖃᑎᒋᓗᒍ ᐋᓐᓂᐊᖅᑲᖅᑕᐃᓕᒪᔪᓕᕆᔨᒋᔭᐃᑦ. ᐅᖃᓗᒃᕕᒋᔪᖕᓇᖅᑕᑎᑦᑕᐅᖅ ᐋᓐᓂᐊᖅᑲᖅᑕᐃᓕᒪᔪᓕᕆᔨᒃᑯᑦ Health Links-Info Santé ᐅᐃᓂᐲᒻᒥᑦ ᐅᕗᖓ 204-788-8200 ᐅᕝᕙᓘᓐᓃᑦ 1-888-315-9257 (ᐅᖃᓗᑎ ᐊᑭᖃᖕᒋᑦᑐᖅ ᒫᓂᑑᐸᒥᑦ).

ᑲᓇᑕᒥᑦ ᓄᓇᒋᔭᐅᔪᖅ ᒫᓂᑑᐸ:

www.manitoba.ca/covid19/index.html

ᑲᓇᑕᒥᑦ ᒐᕙᒪᒃᑯᑦ:

https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19.html